As of May 29, 2025, AngioDynamics Inc (ANGO) reports a ROE (Return on Equity) of -89.67%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of AngioDynamics Inc's ROE (Return on Equity)
Over recent years, AngioDynamics Inc's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-05-31 | -89.67% |
| 2023-05-31 | -13.85% |
| 2022-05-31 | -6.24% |
| 2021-05-31 | -7.17% |
| 2020-05-31 | -36.67% |
This slight upward trend highlights how AngioDynamics Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing AngioDynamics Inc's ROE (Return on Equity) to Peers
To better understand AngioDynamics Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| AngioDynamics Inc (ANGO) | -89.67% |
| Intersect Ent Inc (XENT) | 231.11% |
| Cutera Inc (CUTR) | 94.76% |
| IDEXX Laboratories Inc (IDXX) | 55.65% |
| Edwards Lifesciences Corp (EW) | 41.75% |
| Kewaunee Scientific Corp (KEQU) | 34.25% |
Compared to its competitors, AngioDynamics Inc's ROE (Return on Equity) is among the lowest compared to peers, which may indicate less effective deployment of shareholders' capital.